Safe-Cross vessel wall detection technology approved in the US:
This article was originally published in Clinica
Kensey Nash has received US FDA 510(k) clearance for its vessel wall detection technology. The Safe-Cross RF CTO system combines a guidance system and radiofrequency energy to safely cross and recanalise chronic total occlusions in the coronary and peripheral arteries. The clearance allows Kensey Nash, of Exton, Pennsylvania, to incorporate a new interferometer with greater dynamic range into the Safe-Cross console. This technology will allow the system to sense the vessel wall farther in advance, allowing the operator more time to adjust the direction of the wire. The updated console will undergo a period of user evaluations prior to broader market introduction. Kensey Nash expects to CE mark the new technology later this year.
You may also be interested in...
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.